MGX
Metagenomi
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About MGX
Metagenomi, Inc.
A precision gene editing biotechnology company
Biological Technology
Invalid Date
02/09/2024
NASDAQ Stock Exchange
202
12-31
Common stock
5959 Horton Street, 7th Floor, Emeryville, California 94608
--
Metagenomi, Inc., was incorporated in Delaware in September 2016. The company is a precision genetic medicine company dedicated to the development of therapeutic drugs for patients using a proprietary, comprehensive metagenomics-derived genome editing toolkit. Inherited diseases are caused by a series of different mutations that have so far been largely unavailable with genomic engineering methods. Gene mutations occur in many forms, including deletions, insertions, single-base pair changes, and sequence repeats, and are found throughout the genome and in a variety of different cell types, tissues, and organ systems.
Company Financials
EPS
MGX has released its 2024 Q4 earnings. EPS was reported at -0.37, versus the expected -0.78, beating expectations. The chart below visualizes how MGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MGX has released its 2024 Q4 earnings report, with revenue of 9.61M, reflecting a YoY change of -22.46%, and net profit of -23.40M, showing a YoY change of -21.27%. The Sankey diagram below clearly presents MGX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
